Topics: Research
In this 35‑minute video, Sara Cotter, founder and CEO of Levo Therapeutics, joins other members of the Levo team in describing the company’s mission of developing impactful therapies for the PWS community. The session includes Q&A from participan...
Harmony Biosciences recently announced changes to their Phase 2 Clinical Trial of Pitolisant that reduce the requirements of participating in the study.
Topics: Research
A special contribution by guest blogger Jeannine Kowal, FPWR Board President Share your story via our Stories of Hope Questionnaire. Caitlin's birth was uneventful. Caitlin's birth was induced at thirty‑nine and a half weeks because of growth concern...
Topics: Stories of Hope
In this one hour and 9‑minute video, Dr. Lauren Schwartz Roth, a clinical psychologist and parent to a young adult with PWS, explains how parents and caregivers can effectively assess and manage mental health issues if they arise in loved ones with P...
Topics: Research
ARD-101 is a new, oral therapeutic that has shown promising activity in reducing appetite and promoting weight loss in preclinical (animal model) studies.
Topics: Research
In this 60‑minute video, Janice Agarwal, a Pediatric Physical Therapist, explains how children with PWS have decreased sensory awareness and how you can help your child with sensory integration. The session includes Q&A from participants in the 2...
Topics: Research
In this 67‑minute video, Dr. Theresa Strong and the FPWR Research Team share highlights of projects we are currently advancing. The session includes Q&A from participants in the 2021 FPWR Virtual Conference.
Topics: Research
Research at a Glance: A new test, funded in part by FPWR, has been designed to simultaneously screen newborns for three rare genetic disorders In a recent study, the test was found to be feasible, reliable, and scalable Screening for Prader Willi, An...
Topics: Research
Soleno Therapeutics has provided an update following recent interactions with the U.S. Food and Drug Administration (FDA) regarding the development of once-daily DCCR (diazoxide choline) extended-release tablets for the treatment of Prader-Willi synd...
Topics: Research